Organization | GU Research Network, LLC

GU Research Network, LLC Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2012

NCT01751451

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (2)

abiraterone (zytiga) (2 trials)

methylprednisolone (medrol) (1 trial)

Drugs in Phase 2 Trials (6)

ags-003 (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

degarelix acetate (firmagon) (1 trial)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 8